Systemic and long‐term delivery of IL‐10 has been associated with flu‐like symptoms, anemia, thrombocytopenia, elevated liver transaminase levels, and injection site reactions (Patilas et al., 2024), emphasizing the need for novel and directed IL‐10 administration strategies. This evidence concerns the gene IL10 and Thrombocytopenia.